Nanomedicine as a potential approach to empower the new strategies for the treatment of preeclampsia

被引:29
作者
Valero, Lucie [1 ,2 ,3 ,4 ,5 ]
Alhareth, Khair [1 ,2 ,3 ,4 ]
Gil, Sophie [3 ,5 ,7 ]
Lecarpentier, Edouard [3 ,5 ]
Tsatsaris, Vassilis [3 ,5 ,6 ,7 ]
Mignet, Nathalie [1 ,2 ,3 ,4 ]
Fournier, Thierry [3 ,5 ,7 ]
Andrieux, Karine [1 ,2 ,3 ,4 ]
机构
[1] PSL Res Univ, Chim ParisTech, UTCBS, F-75005 Paris, France
[2] UTCBS, CNRS, UMR 8258, F-75006 Paris, France
[3] Univ Paris 05, Sorbonne Paris Cite, F-75006 Paris, France
[4] UTCBS, INSERM, U 1022, F-75006 Paris, France
[5] INSERM, UMR S1139, Fac Pharm Paris, F-75006 Paris, France
[6] Hop Cochin, AP HP, F-75014 Paris, France
[7] Fondat PremUp, F-75006 Paris, France
关键词
TYROSINE KINASE-1; CANCER-DIAGNOSIS; PLACENTAL SFLT1; LIPOSOMES; PREGNANCY; CELL; FUTURE; MODEL; SYNCYTIOTROPHOBLAST; HYPERTENSION;
D O I
10.1016/j.drudis.2018.01.048
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Preeclampsia is a serious pregnancy disorder characterized by the onset of high blood pressure and proteinuria. Although the understanding of the disease is increasing, it remains without treatment, other than the delivery of the baby and the placenta. This review sets out to discuss some new developments and strategies in the treatment of preeclampsia. We briefly review the current knowledge on the preeclamptic pathophysiology. We then examine the recent trends in preeclampsia treatment and, in particular, the tracks of potential therapeutic targets. Finally, we focus on the possibilities nanocarriers could offer in the management of preeclampsia. Indeed, nanocarriers could help to prevent transplacental passage and promote placental-specific drug delivery, thereby enhancing efficacy and improving safety. Tendencies are then drawn from the available studies on the optimal characteristics of a nanocarrier to deliver drugs to the placenta.
引用
收藏
页码:1099 / 1107
页数:9
相关论文
共 67 条
[11]   Therapeutic potential of resveratrol:: the in vivo evidence [J].
Baur, Joseph A. ;
Sinclair, David A. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (06) :493-506
[12]   Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction [J].
Brownfoot, Fiona C. ;
Hastie, Roxanne ;
Hannan, Natalie J. ;
Cannon, Ping ;
Tuohey, Laura ;
Parry, Laura J. ;
Senadheera, Sevvandi ;
Illanes, Sebastian E. ;
Kaitu'u-Lino, Tu'uhevaha J. ;
Tong, Stephen .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (03) :356.e1-356.e15
[13]   YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia [J].
Brownfoot, Fiona C. ;
Tong, Stephen ;
Hannan, Natalie J. ;
Hastie, Roxanne ;
Cannon, Ping ;
Tuohey, Laura ;
Kaitu'u-Lino, Tu'uhevaha J. .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2015, 413 (0C) :202-208
[14]   Rheological and Physiological Consequences of Conversion of the Maternal Spiral Arteries for Uteroplacental Blood Flow during Human Pregnancy [J].
Burton, G. J. ;
Woods, A. W. ;
Jauniaux, E. ;
Kingdom, J. C. P. .
PLACENTA, 2009, 30 (06) :473-482
[15]   Placental oxidative stress: From miscarriage to preeclampsia [J].
Burton, GJ ;
Jauniaux, E .
JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2004, 11 (06) :342-352
[16]   Developmental biology - One cell, two fates [J].
Carmeliet, P .
NATURE, 2000, 408 (6808) :43-45
[17]   The therapeutic potential of antioxidants, ER chaperones, NO and H2S donors, and statins for treatment of preeclampsia [J].
Cindrova-Davies, Tereza .
FRONTIERS IN PHARMACOLOGY, 2014, 5
[18]   Nanotechnology: Intelligent design to treat complex disease [J].
Couvreur, Patrick ;
Vauthier, Christine .
PHARMACEUTICAL RESEARCH, 2006, 23 (07) :1417-1450
[19]   Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1 [J].
Cudmore, Melissa ;
Ahmad, Shakil ;
Al-Ani, Bahjat ;
Fujisawa, Takeshi ;
Coxall, Heather ;
Chudasama, Kunal ;
Devey, Luke R. ;
Wigmore, Stephen J. ;
Abbas, Allyah ;
Hewett, Peter W. ;
Ahmed, Asif .
CIRCULATION, 2007, 115 (13) :1789-1797
[20]   Resveratrol inhibits the release of soluble fms-like tyrosine kinase (sFlt-1) from human placenta [J].
Cudmore, Melissa J. ;
Ramma, Wenda ;
Cai, Meng ;
Fujisawa, Takeshi ;
Ahmad, Shakil ;
Al-Ani, Bahjat ;
Ahmed, Asif .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2012, 206 (03)